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3-4) with no increase in relapse (17% at 1-year).
Conclusions: These data demonstrate translation of our
experimental observations into a novel proof-of-concept
phase I/II clinical trial of vorinostat in reducing the incidence
of GVHD.3
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Using methods to inhibit the NFkB family member c-Rel,
a transcription factor that upon antigen receptor triggering
regulates lymphocyte survival and proliferation, we devel-
oped a novel strategy to diminish alloactivation of T cells
while preserving GVT activity.
We investigated the role of c-Rel during GVHD in MHC
mismatched as well as MHC matched, minor antigen mis-
matched murine HSCT models. c-Rel-/- T cells caused signif-
icantly less GVHD than normal T cells, as determined by
survival (p<0.001), clinical GVHD score (p<0.01), and
histopathology of GVHD target organs. On day 3 post trans-
plant, proliferation and activation of c-Rel-/- T cells was
impaired (p<0.001 CFSElow/high ratio; p<0.01 CD25þ donor
cells) and pSTAT5 expression was decreased (p<0.05),
resulting in less expansion of donor derived effector Tcells by
day 7 after transplant (p<0.001). Unexpectedly, serum levels
of IL-2 were increased on day 7, likely secondary to decreased
pSTAT5-mediated negative feed back on IL-2 secretion. In
addition, IL-21, a target gene of c-Rel and negative regulator
of IL-2, was decreased (p<0.05) in recipients of c-Rel-/- T cells
during early GVHD. By day 14 post BMT we observed
increased numbers of donor derived Tregs with increased
CD25 expression in recipients of c-Rel-/- T cells (p<0.05),
suggesting that the increased IL-2 levels primarily beneﬁted
the expansion of Tregs. Consistent with this hypothesis, in
vivo depletion of donor Tregs in recipients of c-Rel inhibited
Foxp3DTR transgenic T cells exacerbated GVHD.
We next evaluated if c-Rel deﬁcient T cells were able to
mediate antitumor activity. We challenged allogeneic HSCT
recipients with either a liquid tumor (A20) or a solid tumor
(RENCA) and found that GVT activity in c-Rel-/- T cells
recipients was intact in the absence of GVHD, resulting in
signiﬁcantly improved survival compared to recipients of
wildtype T cells (p<0.001 A20; p<0.01 RENCA). Using
syngeneic GVT models with EL4 as well as B16 we could
demonstrate strong anti-tumor activity of c-Rel deﬁcient
polyclonal T cells targeting EL4 as well as melanoma antigen-
speciﬁc pmel-1 transgenic T cells in the absence of T cell
alloactivation, reinforcing the notion of separation of GVHD
from GVT activity through inhibition of c-Rel signaling.
The potential for clinical translation of our approach is
highlighted by a series of experiments testing the efﬁcacy of
a recently developed Pyrimidinetrione-based small molecule
c-Rel inhibitor compound. Using T cells that were pre-incubated with this c-Rel inhibitor, we reproduced our above
described effects on GVHD and antitumor activity (Figure 1).
Taken together, our ﬁndings identify c-Rel as a promising
target for the development of a clinical strategy to prevent
GVHD while preserving GVT activity, and to possibly even
enable adoptive T cell therapy across MHC barriers that
would be incompatible with a conventional transplant
approach.
Figure 1. Pre-incubation of donor T cells with a c-Rel antagonist prevents
GVHD while preserving GVT activity.
(A-C) Lethally irradiated (8.5Gy) BALB/c recipients received 5  106 WT B6
TCD-BM cells with 0.5  106 WT B6 CD5+ T cells after 24 hours of pre-
incubation with a c-Rel antagonist. Control mice received 5  106 WT B6 TCD-
BM cells with 0.5  106 WT B6 CD5+ T cells that were pre-incubated with
empty vehicle control solution. On day 0, HSCT recipients were challenged
with 0.25  106 luciferase-expressing A20-TGL tumor cells. Data are repre-
sentative of at least two independent experiments; n ¼ 5-8. Error bars indicate
SEM. *P<0.05; ***P<0.001. (A) Survival curve. (B) Body weight changes. (C)
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Historical data are conﬂicting as to whether superior
outcomesoccurwith cyclophosphamide (CY)þTBI compared
to oral busulfan (BU)-based myeloablative conditioning
regimens. IV BUwith orwithout pharmacokineticmonitoring
is better tolerated than oral BU. To testwhethermyeloablative
IVBU-basedconditioning regimens result in similaroutcomes
to traditional TBI-based conditioning, we conducted
a prospective multi-center cohort study comparing these 2
approaches in patients with myeloid malignancies (AML,
MDS, CML) undergoing matched related or unrelated donor
blood or marrow transplants. All patients received myeloa-
blative conditioning intensity (IV BU (>9mg/kg) plus Cy (60
mg/kg) or ﬂudarabine (80mg/m2); TBI (500cGy in a single
fraction or 800 cGy fractionated) plus Cy (60 mg/kg) or
etoposide (30 mg/kg)) and calcineurin-inhibitor based
